220 related articles for article (PubMed ID: 19843143)
1. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.
Delgallo WD; Rodrigues JR; Bueno SP; Viero RM; Soares CT
Cytopathology; 2010 Aug; 21(4):259-66. PubMed ID: 19843143
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
3. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
4. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
6. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
9. Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
[TBL] [Abstract][Full Text] [Related]
10. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
[TBL] [Abstract][Full Text] [Related]
13. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S
Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993
[TBL] [Abstract][Full Text] [Related]
14. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
Verma S; Bal A; Joshi K; Arora S; Singh G
APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
17. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
18. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast.
Lester T; Wang J; Bourne P; Yang Q; Fu L; Tang P
Ann Clin Lab Sci; 2009; 39(1):17-24. PubMed ID: 19201736
[TBL] [Abstract][Full Text] [Related]
19. [Actins and keratins in the diagnosis of human basal-like breast cancer].
Dugina VB; Ermilova VD; Chemeris GIu; Chipysheva TA
Arkh Patol; 2010; 72(2):12-5. PubMed ID: 20698309
[TBL] [Abstract][Full Text] [Related]
20. Mesothelial markers in high-grade breast carcinoma.
Duhig EE; Kalpakos L; Yang IA; Clarke BE
Histopathology; 2011 Nov; 59(5):957-64. PubMed ID: 22092407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]